Significance of virological diagnostics for the effective treatment of hospitalized patients infected with influenza virus;Znaczenie diagnostyki wirusologicznej dla skuteczności leczenia hospitalizowanych chorych zakażonych wirusem grypy

Pneumonologia i Alergologia Polska

Volumn 74, Issue 2, 2006, Pages

  Machała, Magdalena ^a   Wiatr, Elzbieta ^b   Gawryluk, Dariusz ^b   Brydak, Lidia B ^a  

^a NATIONAL INSTITUTE OF HYGIENE   (Poland)

^b Immun Inst Gruzlicy i Chorob Pluc   (Poland)

Author keywords

Amantadine; Infection; Influenza; Oseltamivir; Virus

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; OSELTAMIVIR; RIMANTADINE; ZANAMIVIR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG EFFICACY; HIGH RISK POPULATION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; IMMUNOFLUORESCENCE; INFLUENZA; INFLUENZA VIRUS; LABORATORY DIAGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIROLOGY;

EID: 33749416234     PISSN: 08677077     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Boivin G. i wsp. Predicting influenza infections during epidemics with use of clinical case definition. Clin. Infect. Dis. 2000, 31, 1166-1169.
2. Brydak L. B. Grypa i jej profilaktyka. Wyd. II, Termedia, Poznań 2004, 1-272.
3. Brydak L. B.: Grypa istotnym problemem zdrowia publicznego w Polsce. Family Medicine & Primary Care Review, 2005 7(2), 261-271.
4. Brydak L. B., Machała M.: Inhibitory neuraminidazy wirusa grypy. Przewodnik Lekarza 2001, 7-8(31-32), 55-60.
5. Centers for Disease Control and Prevention. WHO Collaborating Center for the Surveillance, Epidemiology and Control of Influenza. Concepts and procedures for laboratory-based influenza surveillance. U.S. Department of Health and Human Services, Public Health Service, July 1982.
6. Centers for Disease Control and Prevention, Department of Health and Human Services: Detection & Control of Influenza Outbreaks in Acute Care Facilities, CDC 2001.
7. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2005, 54 (no. RR-8): 1-40.
8. Centers for Disease Control and Prevention: High levels of adamantane resistance among influenza A (H3N2) viruses and interim guidelines for use of antiviral agents - United States, 2005-06 influenza season. MMWR Morb. Mortal. Wkly Rep. 2006, 55(2), 44-46.
9. de Jong M. D. i wsp. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med 2005, 353, 25, 2667-2672.
10. ESWI Lab Course, Basic Laboratory Methods for Influenza Diagnosis - For use in National Influenza Centers and Correspondant Laboratories. Institut Pasteur, Paris, 17-21 July 2000.
11. Manuguerra J.-C., Hannoun C.: Influenza and other viral respiratory diseases. Surveillance and laboratory diagnosis. Institut Pasteur, Paris 1999, 1-286.
12. Monto A. S. i wsp. Clinical signs and symptoms predicting influenza infection. Arch. Intern. Med. 2000, 160, 3243-3247.
13. Moscona A.: Neuraminidase inhibitors for influenza. N. Engl. J. Med. 2005, 353, 13, 1363-1373.
14. Nicholson K. G. i wsp. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomized controlled trial. The Lancet 2000, 355, 1845-1850.
15. van Essen G. A.: Results of the ESWI-Nivel survey on vaccination rate in at-risk groups in Poland in 2003. Polish Influenza Network Meeting, 30 November 2004, Warsaw.